EP2131825A1

EP2131825A1 - Mineralcorticoid receptor antagonists for the treatment of endometriosis

Info

Publication number: EP2131825A1
Application number: EP08717238A
Authority: EP
Inventors: Carsten Moeller; Ulrike Kaufmann-Reiche; Anja Schmidt; Ulrike Fuhrmann; Oliver-Martin FISCHER
Original assignee: Bayer Schering Pharma AG
Current assignee: Bayer Intellectual Property GmbH
Priority date: 2007-03-02
Filing date: 2008-02-28
Publication date: 2009-12-16
Also published as: WO2008107373A1; RU2009136305A; IL200380A0; KR20090119870A; MX2009009332A; CA2679520A1; BRPI0808427A2; AU2008223859A1; AR065585A1; TW200900080A; CN101621995A; JP2010520178A; DE102007011105A1; US20110003778A1

Abstract

The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endometriosis, which has a more favorable effectiveness profile and/or profile of side effects than previously available treatment therapies. With a mineralcorticoid receptor antagonist, endometriosis can be lastingly treated without resulting in a loss of bone mass.

Description

Mineralocorticoid receptor antagonists for the treatment of endometriosis

The present invention relates to the use of mineralocorticoid receptor antagonists for the treatment of endometriosis. In particular, the present invention relates to a better therapeutic agent against endometriosis, which shows a better effect or side effect profile than previously available treatment therapies.

The clinical picture of endometriosis is a dislocation of endometrial tissue outside the uterine cavity. These so-called endometriotic lesions nest at different sites of the peritoneal cavity, e.g. the intestinal wall, on the ovary or rectovaginal and maintain the properties of their original tissue. Endometriosis is essentially inflammatory and affects 10-20% of women of reproductive age. The core symptoms of endometriosis are chronic abdominal pain, dysmenorrhea, dyspareunia, dysuria, bleeding disorders and infertility. The symptoms are mostly combined. It is assumed that the lesions pass through the fallopian tube into the peritoneal space through retrograde menstruation and then settle there.

Current therapeutic approaches for the treatment of diagnosed endometriosis are very limited. They include the use of GnRH agonists, androgens or progestins.

GnRH agonists suppress endogenous estrogen production by interfering with the hypothalamic / pituitary / ovarian axis. This leads to a reduction in estrogen levels to postmenopausal levels and, concomitantly, a reduction in endometriosis-related symptoms. Androgens work similarly, with an additional direct effect on the ovary is postulated. Due to their side-effect profile, both therapeutic approaches are only suitable for short-term use (6-9 months).

GnRH agonists induce postmenopausal symptoms such as hot flashes and decreased bone mass. Acne, weight gain and irreversible mood swings can also be observed with androgens. At present, Depot-MPA (medroxyprogesterone acetate) is the only progestogen approved for endometriosis treatment. Already after a period of use of 6 months it can lead to a reduction of the bone mass. Therefore, it should under no circumstances be used over a period longer than 2 years (Physician Information on depo-subQ provera 104; Subcutaneous Depot medroxyprogesterone acetate versus leuprolide acetate in the treatmant of endometriosis associated pain; PG Crosignani et al., Human Reproduction Vol. 21 , No. 1 pp. 248-256, 2006).

An indication that micronized drospirenone is suitable for the treatment of endometriosis can be found in EP 1 257 280 B1: it is described there in [0045] that compositions of drospirenone with a low content of estrogen or even without any estrogen, and the like. a. should be suitable for the treatment of endometriosis. This is related to the gestagenic property of drospirenone in the context of this disclosure. Drospirenone is therefore described as suitable for the treatment of endometriosis because of its gestagenen effectiveness. In EP 1 257 280 B1 amounts of 0.5 to 10 mg drospirenone are described as effective. About the duration of the treatment of endometriosis with drospirenone in EP 1 257 280 B1, nothing is said.

Furthermore, endometriosis can be treated by surgical removal of the endometriotic lesions in a laparoscopic procedure. The relapse rate after such an intervention is very high (25-30%). Hysterectomy, ie the complete removal of the uterus, is the final therapy option in such particularly stubborn cases.

Therefore, there are currently no long-term endometriosis treatment regimens that combine a balance of adverse events, treatment efficacy, and relapse rates.

The object of the present invention is to provide new therapeutic approaches for the treatment of endometriosis, which show a better effect or side effect profile than previously available treatment therapies. In particular, the therapeutic approach according to the invention is intended to make possible a long-term or long-term treatment of endometriosis.

The present invention solves the problem with a new therapeutic approach for the long-term treatment of endometriosis. According to the invention, mineralocorticoid receptor antagonists are used for the preparation of a medicament for the treatment of endometriosis.

The duration of treatment with the mineralocorticoid receptor antagonist can over a

Period of at least 6 months, preferably longer than 24 months.

Should be treated for a shorter period than 6 months, then drospirenone as

Mineralocorticoid Receptor Antagonist Excluded.

The mineralocorticoid receptor antagonists may be used alone or in combination with other substances.

In such combined applications, the insert together with at least one compound from the group of

• progestogens,

• SERMs (Selective Estrogen Receptor Modulators),

SPRMs (Selective Progesterone Receptor Modulators),

Combinations of progestogens and estrogens,

Progesterone receptor antagonists,

Estrogen receptor antagonists,

Glucocorticoids,

Estrogen receptor isotype-specific ligands (ER-β ligands),

• androgens,

• Antiandrogens and the

• SARMs (Selective Androgen Receptor Modulators)

prefers.

This invention also relates to the use of compounds which combine their anti-mineralocorticoid activity with action on other receptors for the manufacture of a medicament for the treatment of endometriosis.

Preference is given here to substances which are both antimineralocorticoid and moreover exhibit an action on the progesterone receptor, on the estrogen receptor, on the estrogen receptor beta, on the glucocorticoid receptor and / or on the androgen receptor, this effect on the latter receptors being both agonistic , can be partial agonist as well as antagonistic. Mineralocorticoid receptor antagonists are substances which have a binding affinity to the mineralocorticoid receptor and inhibit the action of the natural mineralocorticoid aldosterone. Examples include the compounds spironolactone, Epleronone and drospirenone. The mineralocorticoid receptor antagonists to be used according to the invention should have a binding affinity at the mineralocorticoid receptor which is approximately equal to or better than that of the aldosterone. Mineralcorticoid receptor antagonists are only those substances that block the aldosterone at its receptor, but not those that inhibit the endogenous production of aldosterone

For the purposes of the present invention, progestins are understood to be either the natural progesterone itself or synthetic derivatives which, like the progesterone itself, bind to the progesterone receptor and inhibit ovulation in dosages which are above the ovulation inhibitor dose. Examples of the synthetic derivatives include drospirenone, gestodene, levonorgestrel, cyproterone acetate, desogestrel and 3-ketodesogestrel, norethisterone, norethisterone acetate and dienogest.

According to the invention, SERMs (Selective Estrogen Receptor Modulators) are compounds which either have an antiestrogenic or estrogenic effect on the tissue, for example inhibit the action of the estrogen on the uterus but have a neutral or estrogen-like effect on the bone. Examples include tamoxifen, raloxifene and basidoxifen.

In the context of the present invention, SPRMs (Selective Progesterone Receptor Modulators, sometimes also referred to as mesoprogestins) are compounds which have both agonistic and antagonistic activity in vivo on the progesterone receptor. Like progesterone and progesterone receptor antagonists, the SPRMs show a high binding affinity to the progesterone receptor. However, the SPRMs have other pharmacodynamic properties compared to the progestins or progesterone receptor antagonists. Progesterone agonist activity determined in vivo by common biological tests (for example, in the McPhail Test, Selye, H.) of SPRMs is the fundamental property of these compounds. However, this activity lags behind that of progesterone. A pregnancy preservation in ovaretomierten pregnant rodents, such as the mouse or the rat, does not succeed with SPRMs. On the other hand, SPRMs antagonize the action of progesterone. However, the maximum antagonizing effect is less than that which can be induced by RU 486 or another pure progesterone antagonist. For further embodiments, for example, the WO Referenced 01/15679. Typical representatives of this class of compounds are 4- [17β-methoxy-17α- (methoxymethyl) -3-oxoestra-4,9-dien-11β-yl] benzaldehyde (1E) -oxime, 4- [17β-

Methoxy-17α- (methoxymethyl) -3-oxoestra-4,9-diene-1 1β-yl] benzaldehyde (1 E) - [O- (ethylamino) carbonyl] oxime and the 4- [17β-methoxy-17α - (methoxymethyl) -3-oxoestra-4,9-diene-1 1 ß-yl] benzaldehyde (1 E) - [O- (ethylthio) carbonyl] oxime called.

SARMs (Selective Androgen Receptor Modulators) are substances which have a tissue-selective androgenic or anti-androgenic action, such as anti-androgenic effects on the skin, but have no or positive effect on libido.

Combinations of progestogens and estrogens are the active ingredient combinations contained in the conventional oral contraceptives, for example, Yasmin, Femovan, Triquilar, Marvelon, YAZ, etc.

Progesterone receptor antagonists are compounds that inhibit the action of progesterone on its receptor. As examples, RU486, onapristone and 1-1β- (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2,2-pentafluoroethyl) estra-4,9-dien-3-one (WO 98/34947).

Estrogen receptor antagonists are compounds that block the action of the estrogen on its receptors (estrogen receptor α and estrogen receptor β). As the estrogen receptor α blocking compound is, for example, 7α- [9- (4,4,5,5,5-pentafluoropentylsulfinyl] -n-nonyl] -estra-1, 3,5 (10) -triene-3,17β- to call diol.

Glucocorticoids are compounds which induce agonistic action on the glucocorticoid receptor and thus have an immunosuppressive effect. As an example, the dexamethasone is mentioned.

According to the invention, the mineralcorticoid receptor antagonists are used in the following dosages:

Spironolactone 10 to 500 mg / d and person, single dose or in 2 halves, preferably 25 to

250;

Eplerenone 10 to 500 mg / d and person, single dose or in half, preferably 25 to 250;

Drospirenone 1 to 5 mg, preferably 2 to 4 mg.

Other mineral corticosteroid receptor antagonists are used in equivalent dosages, that is dosages comparable to those of the above compounds in the treatment of endometriosis. When the mineralocorticoid receptor antagonists are used together with another compound (see above), these compounds will be used in the dosage ranges already described for these other compounds.

The mineralcorticoid receptor antagonists and any further compounds to be used are formulated in a manner known to the person skilled in the art.

The classic physiological function of aldosterone as an effector of the renin-angiotensin-aldosterone system is the regulation of extracellular volume and the homeostasis of the potassium balance. Activation of the mineralocorticoid receptor, however, may occur in various tissues which exhibit expression of the mineralocorticoid receptor, such as e.g. the brain, the heart or blood vessels, lead to pathological phenomena. Examples include hypertension, vascular diseases, renal failure, migraine, neuropathy, retinopathy, baroreceptor dysfunctions, liver diseases and edema called. It is postulated that these harmful effects of aldosterone by the mineralocorticoid receptor in the non-classical target organs, such. As the blood vessels are caused (Rudolph et al., 2004).

The effect of the aldosterone on the target organ kidney results in the action of the diuretics spironolactone and epleronone: they increase renal sodium excretion in the presence of aldosterone and reduce potassium excretion. This leads in total to an increased water excretion. They are therefore used in the treatment of hypertension (Weinberger et al., 2002, Weinberger et al., 2005). However, the inhibition of aldosterone with the help of substances such as Epleronon also has a protective effect on various target organs, without this being accompanied by a measurable reduction in blood pressure or without having a diuretic effect (Rudolph et al., 2004). In the animal model, e.g. demonstrated that epleronone inhibits aldosterone-mediated initial inflammatory damage to blood vessels and myocardial fibrosis in myocardial infarction models (Rocha et al., 2002a, Rocha et al., 2002b). Recent in vitro studies indicate that spironolactone can affect the biosynthesis of certain cytokines in cells of the immune system (Mikkelsen et al., 2006).

A physiological or pathophysiological function of aldosterone or mineralocorticoid receptor in the genesis and course of endometriosis has not previously been described. According to the invention, it has now been found that the mineralocorticoid receptor surprisingly has a changed expression profile in endometriosis. This can be determined, for example, by quantitative RT-PCR, in which the mRNA content is measured in comparison to a reference gene. In the pathological tissue, the endometriotic lesions, the mineralocorticoid receptor shows a 2 to 3 times higher mRNA content when compared to the healthy tissue, the endometrium of the uterus (see Figure 1). If one compares the expression of the mineralocorticoid receptor in the endometrium during various stages of the menstrual cycle, no change in the expression level (mRNA content) can be seen (Figure 1). This suggests that aldosterone and the mineralocorticoid receptor have no regulatory function in the normal physiology of the endometrium, ie in the healthy endometrium.

It has also been shown according to the invention that the expression of the mineralocorticoid receptor in endometriotic lesions is also increased in an endometriosis model in rodents (in this case rats), again in comparison to the endometrium of the uterus (Figure 2). The role of the mineralocorticoid receptor in endometriosis therefore appears to be consistent in different species.

In addition, it has been found according to the invention that substances which inhibit the action of aldosterone on the mineralocorticoid receptor show in a primate model on endometriosis an effect which suggests a positive effect in the treatment of endometriosis in humans (Figure 3). In this experiment, the mineralocorticoid receptor antagonist spironolactone, a standard compound within this class of drugs, was used.

On the basis of these observations, which are described in more detail in Examples 1 to 3, it is to be assumed that the treatment of patients with endometriosis with a mineralocorticoid receptor antagonist will lead to a reduced symptom, because the treatment in the primate model both reduces the size which has led to endometriotic lesions as well as inhibiting proliferation in these lesions.

One embodiment of the invention contemplates the use of a combination of mineralocorticoid receptor antagonists with at least one of progesterone, progesterone receptor antagonists, glucocorticoids, a combination of progestogens and estrogens, SERMs, SPRMs, and estrogen receptor isotype-specific ligands (selective ERβ agonists) The use of compounds from these classes of drugs for the treatment of endometriosis is already known. References from the literature are already available for the treatment of endometriosis with SPRMs and progesterone receptor antagonists (Kettel et al., 1996), the same has been described for the use of progestagens and combinations of progestogens and estrogens (Rodgers and Falcone, 2008 ). Furthermore, there is evidence from preclinical animal models that estrogen receptor isotype-specific ligands can positively affect endometriosis (Harris et al., 2005). In addition, it is known that glucocorticoids can have an immunosuppressive effect and therefore can have a positive influence on the course of endometriosis. However, for none of these approaches described is safe long-term use in women described or known. A combination of a mineralocorticoid receptor antagonist with one of these already known principles of action should on the one hand have an additive effect in the effect, on the other hand, however, also allow a long-term application. In this combined therapy, the substances added in addition to the mineralocorticoid receptor antagonist should be used in the pharmacologically effective dosages already described. For example, SPRMs and progesterone receptor antagonists in a dose range of 1 mg to 100 mg per woman per day, with glucorticoids of 0.01 - 2 mg / kg and day.

Particularly suitable in this case is the use of mineralocorticoid receptor antagonists, which simultaneously show either a gestagenic effect, or have a progesterone receptor antagonist activity or a glucocorticoid effect or an estrogen receptor isotype-specific activity.

The application of the mineralcorticoid receptor antagonists can be carried out continuously and discontinuously in all cases.

Preferred are treatment regimens in which the mineral corticosteroid receptor antagonist is given daily.

Particularly preferred are treatment regimens in which the mineral corticoid receptor

Antagonist is administered daily in oral form.

In combinations of mineral corticosteroid receptor antagonists with progestagens, progesterone receptor antagonists, combinations of estrogens and progestins, estrogen receptor isotype-specific ligands, with SERMs, SPRMs and glucocorticoids, these can also be given continuously and discontinuously.

Particularly preferred are combinations of mineral corticoid receptor antagonists and progestins, mineral corticoid receptor antagonists and progesterone receptor antagonists and mineralocorticoid receptor antagonists and combinations of estrogens and

Progestins.

In combinations of mineral corticosteroid receptor antagonists with gestagens are

Treatment schemes are preferred in which the gestagens are given continuously in daily doses.

In a combination of mineral corticosteroid receptor antagonists with combinations of

Estrogens and progestins can be given either continuously or discontinuously. With discontinuous administration, especially 21/7 or 24/4 cycles are preferred

(21 days taking the combination followed by a 7-day break, either by taking a placebo or taking a break from treatment; 24/4 accordingly).

Preferred as progestagens are the compounds medroxyprogesterone acetate, cyproterone

Acetate, levonorgestrel, norgestimate, desogestrel, gestodene, dienogest. In such

Combinations is preferred as estrogen the compound ethinyl estradiol.

In the case of mineralcorticoid receptor antagonists, which additionally has activity on others

Receptors show, in particular compounds are preferred, in addition to progesterone

Receptor are active, or in addition to the androgen receptor as antagonists are active.

Particularly preferred here are mineral corticoid receptor antagonists which show a gestagenic effect at the same time.

These can be given continuously or discontinuously.

Particularly preferred are treatment regimens containing a daily oral dose.

Mineralcorticoid receptor antagonists that also have a gestagenic effect can also be given in conjunction with estrogens.

Particularly preferred as estrogen is ethinyl estradiol.

Such combinations may be given either continuously (daily) or in a discontinuous regimen.

Preferred as such discontinuous treatment regimens are those which provide an application of 24 days followed by a break of 4 days, or those which follow a treatment of 21 days followed by a break of 7 days. Breaks in these

Treatment regimens can be done either by giving placebos or by simple treatment interruption.

The invention will be explained in more detail with reference to the following examples 1 to 3 and the accompanying figures 1 to 3, without wishing to restrict the invention to these examples. Example 1 :

The expression of the mineralocorticoid receptor in human endometriotic lesions was compared to that in the normal human endometrium. For this purpose, the mineral corticoid receptor DNA was isolated from the corresponding tissue biopsies via a phenol-chloroform extraction, rewritten into cDNA by reverse transcription and, correspondingly, in a TaqMan RT-PCR analysis according to the standard protocol on the relative content of the mineral corticoid receptor mineral corticoid ReceptorNA examined. Commercially available primer / probe combinations from BD Biosciences for the mineral corticoid receptor and the control gene cyclophylin A were used as TaqMan probes.

Fig. 1:

Expression of the minaralocorticoid receptor in the endometrium and in endometriotic lesions by quantitative RT-PCR.

In the endometriotic lesions a clearly increased expression is to be recognized compared to the healthy endometrium (compare samples 1-8, with the samples 1 ^* -8 ^* , 1-8 correspond to eight different patients, the endometriotic lesions are highlighted with asterisks). The phase of the menstrual cycle has no influence on the level of expression in the endometrium (compare follicular phase with luteal phase). The expression of the mineralocorticoid receptor in the eutopic endometrium also shows no difference between healthy and endometriosis patients (compare luteal phase with luteal phase endometriosis). All this suggests a function of the mineral corticoid receptor in the pathology of endometriosis.

Compared to the normal endometrium (1-8, left, first group from left, white), MR shows a 2-3-fold increase in mRNA expression in endometriotic lesions (1 ^* -8 ^* , second group from left, black). If one compares healthy endometrium over different stages of the menstrual cycle, no difference in the expression levels can be seen (follokil phase compared to the luteal phase, third group from the right, white, compared to the second group from the right, light gray). The endometrium of endometriosis patients does not differ in MR expression from the healthy patients (luteal phase endometriosis compared to luteal phase, 1st group from right, gray, opposite 2nd group from right, light gray). Example 2:

Expression of the mineralocorticoid receptor in endometriotic lesions was compared to that in the normal endometrium in a rodent model of endometriosis (Matsuzaki et al., 2004). Adult rat females were removed for this purpose in the oestrus endometrial tissue and transplanted in an autologous transplantation at two positions of the peritoneal cavity, once to the colon wall, and once to the peritoneum. The control tissue used in this experimental approach is again the sutured or closed uterus (after removal of the endometrium). Four weeks after setting of the lesions, these were taken out in addition to the control tissue and, accordingly, the mineral corticoid receptor A was isolated from these tissue biopsies by phenol-chloroform extraction, transcribed into cDNA by reverse transcription and finally analyzed in a standard TaqMan RT-PCR analysis. Protocol on the relative content of mineral corticosteroid receptor mineral corticoid receptorNA studied. The lesions show a significantly increased expression of the mineralocorticoid receptor compared to the normal uterus (see Fig. 2). The enhanced expression of the mineral corticoid receptor is thus conserved even in this model and underlines the pathological function of the mineral corticoid receptor in this indication.

Fig. 2:

Expression of the minaralocorticoid receptor in the endometrium and in endometriotic lesions by quantitative RT-PCR in the rat endometriosis model.

The lesions show markedly increased expression of the mineralocorticoid receptor in comparison to the control tissue (see in each case the expression of uterus control, lesion on the peritoneum and lesion on the intestine: a total of 4 animals were used in this experiment (numbers 14, 20, 26 and 32).

In all four animals tested (animals number 14, 20, 26, 32), both lesions (light gray, lesion on the peritoneum, and gray, lesion on the intestine) show an increased expression of the MR compared to the uterine control (black).

Example 3:

The effect of the mineral corticosteroid receptor antagonist spironolactone was tested in a model of endometriosis in non-human primates. Nonhuman primates are the only species other than humans that spontaneously endometriosis under natural conditions form. They are therefore the most relevant model to study this disease. In this model, rhesus macaques are implanted subcutaneously and interperitoneally for endometrial tissue in autologous transplantation for ovariectomy for reproducibility and after 60 days of either artificially induced menstrual cycle with either physiological concentrations of estradiol ( Control) or with a combination of estradiol and spironolactone (30 mg / kd / day). The animals receive in this procedure a depot for estradiol substitution which allows a serum level of 80 to 100 pg / ml. In this way, it is ensured that the endometriotic lesions are exposed to physiological concentrations of estradiol. Depot can eliminate interindividual fluctuations in hormone levels and their impact on outcomes. After the treatment, the size of the endometrial lesions was determined and in a histological analysis the proliferation in these lesions was detected. Compared to control animals, animals treated with spironolactone show a significant reduction of endometriotic lesions (Table 1). Both the staining of the mitotic antigen Ki67 and the corresponding treatment with bromodioxyuridine (BrDU) show a reduction of the proliferation in the abdominal lesions (see Figure 3). The mineral corticosteroid receptor antagonist spironolactone therefore has a positive effect on the genesis of endometriosis.

Table 1 :

Uterine weight and weights of endometrial lesions after 60 days of treatment in a macaque model. Rhesus macaques were implanted in an autologous transplant subcutaneously and intraperitoneally / abdominally several lesions from endometrial tissue. After an artificially induced menstrual cycle, the animals were treated with either estradiol (control) or estradiol and spironolactone for 60 days. Both types of lesions show a reduction in weight after treatment with spironolactone. Treatment with spironolactone has no significant effect on the uterus as such.

Fig. 3:

Investigation of the proliferation rate of endometrial lesions in an endometriosis model in rhesus macaques after treatment with spironolactone.

Both the immunohistological staining with Ki67 (a marker of mitosis) and the corresponding treatment with bromodioxyuridine (BrDU) show that the treatment of endometrial grafts greatly reduces proliferation in the glandular cells of the lesions.

Both the detection of cell division in the endometriotic lesions using Ki67 (upper row) and the incorporation of BrDU (lower row) shows a reduced value in the animals treated with spironolactone (control, left, opposite to spironolactone, right) ,

Claims

claims:

1. Use of mineral corticosteroid receptor antagonists for the manufacture of a medicament for the long-term treatment of endometriosis over a period of at least 6 months.

2. Use of mineral corticosteroid receptor antagonists according to claim 1 over a period of at least 24 months.

3. Use of mineral corticosteroid receptor antagonists other than drospirenone for the manufacture of a medicament for the treatment of endometriosis.

4. Use of spironolactone according to claim 1, 2 or 3.

5. Use of eplerenones according to claim 1, 2 or 3.

6. Use of drospirenone according to claim 1 or 2.

The use of mineral corticosteroid receptor antagonists according to claim 1, wherein said mineral corticosteroid receptor antagonists combine their anti-mineralocorticoid activity with action at other receptors.

8. Use of mineralcorticoid receptor antagonists according to one of claims 1 to 7 together with at least one compound from the group of gestagens, the SERMs (Selective Estrogen Receptor Modulators), SPRMs (Selective Progesterone Receptor Modulators), combinations of progestogens and estrogens, Progesterone receptor antagonists, estrogen receptor antagonists, glucocorticoids, estrogen receptor isotype-specific ligands (ER-β ligands), androgens, antiandrogens, and SARMs (Selective Androgen Receptor Modulators).

9. Use of mineral corticosteroid receptor antagonists according to claim 8 with a glucocorticoid.

10. Use of mineral corticosteroid receptor antagonists according to claim 8 with progesterone receptor antagonists.

1 1. Use of mineral corticosteroid receptor antagonists according to claim 8 with estrogen receptor antagonists.

12. Use of mineralocorticoid receptor antagonists according to claim 8 with estrogen receptor isotype-specific ligands (ERβ ligands).

13. Use of mineral corticoid receptor antagonists according to claim 8 with a gestagen and an estrogen.

14. Use of ethinyl estradiol as estrogen according to claim 13.

15. Use of mineralcorticoid receptor antagonists according to one of claims 1 to 14, characterized in that the application of the mineral corticoid receptor antagonist takes place continuously (daily).

16. Use of mineralcorticoid receptor antagonists according to one of claims 1 to 14, characterized in that the application of the mineralocorticoid receptor antagonist is discontinuous.

17. Use of mineralcorticoid receptor antagonists according to claim 15, characterized in that the application of the mineralocorticoid receptor antagonist takes place daily in oral form.